CTSO
Income statement / Annual
Last year (2025), Cytosorbents Corp's total revenue was $37.06 M,
an increase of 4.13% from the previous year.
In 2025, Cytosorbents Corp's net income was -$8.20 M.
See Cytosorbents Corp,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$37.06 M |
$35.59 M |
$31.08 M |
$34.69 M |
$40.11 M |
$39.45 M |
$22.77 M |
$20.25 M |
$13.38 M |
$8.21 M |
| Cost of Revenue |
$10.57 M
|
$10.47 M
|
$9.13 M
|
$13.96 M
|
$11.05 M
|
$11.05 M
|
$7.36 M
|
$7.49 M
|
$5.52 M
|
$3.95 M
|
| Gross Profit |
$26.49 M
|
$25.13 M
|
$21.95 M
|
$20.73 M
|
$29.06 M
|
$28.40 M
|
$15.40 M
|
$12.76 M
|
$7.86 M
|
$4.25 M
|
| Gross Profit Ratio |
0.71
|
0.71
|
0.71
|
0.6
|
0.72
|
0.72
|
0.68
|
0.63
|
0.59
|
0.52
|
| Research and Development Expenses |
$5.09 M
|
$6.92 M
|
$15.59 M
|
$15.12 M
|
$16.38 M
|
$8.81 M
|
$12.09 M
|
$7.72 M
|
$4.05 M
|
$4.78 M
|
| General & Administrative Expenses |
$0.00
|
$0.00
|
$37.87 M
|
$2.21 M
|
$38.48 M
|
$31.51 M
|
$24.47 M
|
$22.88 M
|
$15.43 M
|
$12.28 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$435.05 K
|
$582.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$35.65 M
|
$0.00
|
$38.31 M
|
$2.79 M
|
$38.48 M
|
$31.51 M
|
$24.47 M
|
$22.88 M
|
$15.43 M
|
$12.28 M
|
| Other Expenses |
$0.00
|
$35.00 M
|
$0.00
|
$34.34 M
|
-$3.06 M
|
-$1.55 M
|
-$2.18 M
|
-$2.25 M
|
-$1.77 M
|
-$1.32 M
|
| Operating Expenses |
$40.73 M
|
$41.91 M
|
$53.90 M
|
$52.25 M
|
$51.81 M
|
$38.77 M
|
$34.38 M
|
$28.35 M
|
$17.71 M
|
$15.74 M
|
| Cost And Expenses |
$51.30 M
|
$52.38 M
|
$63.03 M
|
$66.21 M
|
$62.85 M
|
$49.82 M
|
$41.74 M
|
$35.84 M
|
$23.22 M
|
$19.70 M
|
| Interest Income |
$0.00
|
$0.00
|
$0.00
|
$133.00 K
|
$28.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$2.61 M
|
$1.40 M
|
$157.89 K
|
$0.00
|
$0.00
|
$1.20 M
|
$1.03 M
|
$1.46 M
|
$749.08 K
|
$231.80 K
|
| Depreciation & Amortization |
$1.50 M
|
$1.57 M
|
$2.02 M
|
$882.62 K
|
$1.13 M
|
$660.79 K
|
$581.53 K
|
$390.55 K
|
$218.27 K
|
$161.61 K
|
| EBITDA |
-$12.74 M |
-$15.22 M |
-$27.88 M |
-$30.00 M |
-$21.62 M |
-$9.71 M |
-$18.74 M |
-$15.98 M |
-$8.17 M |
-$11.86 M |
| EBITDA Ratio |
-0.34
|
-0.43
|
-0.9
|
-0.86
|
-0.54
|
-0.25
|
-0.82
|
-0.79
|
-0.61
|
-1.45
|
| Operating Income Ratio |
-0.38
|
-0.47
|
-1.03
|
-0.91
|
-0.57
|
-0.26
|
-0.83
|
-0.77
|
-0.74
|
-1.4
|
| Total Other Income/Expenses Net |
$5.64 M
|
-$5.62 M
|
$1.89 M
|
-$2.38 M
|
-$2.55 M
|
$1.41 M
|
-$1.38 M
|
-$2.25 M
|
$705.06 K
|
-$589.88 K
|
| Income Before Tax |
-$8.60 M
|
-$22.41 M
|
-$30.06 M
|
-$33.91 M
|
-$25.29 M
|
-$8.96 M
|
-$20.36 M
|
-$17.83 M
|
-$9.14 M
|
-$12.26 M
|
| Income Before Tax Ratio |
-0.23
|
-0.63
|
-0.97
|
-0.98
|
-0.63
|
-0.23
|
-0.89
|
-0.88
|
-0.68
|
-1.49
|
| Income Tax Expense |
-$401.00 K
|
-$1.69 M
|
-$813.74 K
|
-$1.09 M
|
-$736.00 K
|
-$1.13 M
|
-$1.09 M
|
-$619.55 K
|
-$676.74 K
|
-$318.55 K
|
| Net Income |
-$8.20 M
|
-$20.72 M
|
-$29.25 M
|
-$32.81 M
|
-$24.56 M
|
-$7.84 M
|
-$19.27 M
|
-$17.21 M
|
-$8.46 M
|
-$11.94 M
|
| Net Income Ratio |
-0.22
|
-0.58
|
-0.94
|
-0.95
|
-0.61
|
-0.2
|
-0.85
|
-0.85
|
-0.63
|
-1.45
|
| EPS |
-0.13 |
-0.38 |
-0.65 |
-0.75 |
-0.57 |
-0.2 |
-0.6 |
-0.56 |
-0.31 |
-0.47 |
| EPS Diluted |
-0.13 |
-0.38 |
-0.65 |
-0.75 |
-0.57 |
-0.2 |
-0.6 |
-0.56 |
-0.31 |
-0.47 |
| Weighted Average Shares Out |
$62.23 M
|
$54.43 M
|
$44.66 M
|
$43.57 M
|
$43.36 M
|
$38.82 M
|
$32.26 M
|
$30.72 M
|
$27.61 M
|
$25.43 M
|
| Weighted Average Shares Out Diluted |
$62.23 M
|
$54.43 M
|
$44.66 M
|
$43.57 M
|
$43.36 M
|
$38.82 M
|
$32.26 M
|
$30.72 M
|
$27.61 M
|
$25.43 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
